Vaccines and Related Biological Products Advisory Committee September 20, 2024 by U.S. Food and Drug Administration Facebook Twitter Pinterest LinkedIn The committee will meet in open session to discuss considerations related to the use of pertussis controlled human infection models [CHIMs] in pivotal studies to demonstrate effectiveness of pertussis vaccines for the purpose of licensure. source
